atopic dermatitis

by Elana Gotkine edited by Gaby Clark, reviewed by Andrew Zinin  Editors’ notes  The GIST Add as preferred source Patients with atopic dermatitis (AD) report a desire for climate-health education, which is infrequently addressed by clinicians, according to a research letter published online Jan. 20 in JMIR Dermatology. Gunnar Mattson, M.P.H., M.D., from the University of California in San Francisco,

by Wroclaw Medical University edited by Sadie Harley, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source Molecular targets of biological therapies acting on the IL-31 and IL-33 axis in atopic dermatitis. Credit: International Journal of Molecular Sciences (2025). DOI: 10.3390/ijms262010162 Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and

by Lori Solomon edited by Stephanie Baum, reviewed by Robert Egan  Editors’ notes Credit: Unsplash/CC0 Public Domain The U.S. Food and Drug Administration has approved the supplemental new drug application for Zoryve (roflumilast) cream 0.05% for the topical treatment of mild-to-moderate atopic dermatitis in children 2 to 5 years of age. The once-daily cream can be used

by Lori Solomon edited by Stephanie Baum, reviewed by Robert Egan  Editors’ notes The U.S. Food and Drug Administration has approved Opzelura cream 1.5% (ruxolitinib) for children ages 2 to 11 years with atopic dermatitis (AD). The approval is the first topical Janus kinase (JAK) inhibitor for the short-term, noncontinuous chronic treatment of mild-to-moderate AD in nonimmunocompromised

TOPLINE: Patients with atopic dermatitis (AD) who underwent treatment with dupilumab showed a mean weight gain of 3.6 kg, with 67% of patients experienced an average increase of 5.9 kg. The findings suggested that dupilumab treatment may be associated with weight changes, potentially due to its effect on interleukin-4 signalling and metabolic regulation. METHODOLOGY: Researchers conducted a retrospective chart

by Elana Gotkine edited by Sadie Harley, reviewed by Andrew Zinin In an update to the guidelines for managing atopic dermatitis in adults, four new treatment recommendations are presented. The focused update was published online in the Journal of the American Academy of Dermatology. Dawn M.R. Davis, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues updated previous guidelines issued by

Jennifer Fisher, MMSc, PA-C June 27, 2025 0 59 The American Academy of Dermatology (AAD) recently issued a focused update to its guidelines on the management of atopic dermatitis (AD) in adults, strongly recommending four recently approved therapies: tapinarof cream, roflumilast cream, lebrikizumab, and nemolizumab (in combination with topical therapy). These additions reflect high-certainty evidence